Cyclacel Pharmaceuticals, Inc.Company Review & Valuation

CYCC
Nasdaq

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the frontShow more-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Show less

Industry
Biotechnology
HQ Location
Berkeley Heights, New Jersey
Wikipedia

Stock Price

Price data not available for Cyclacel Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Codexis
Vernalis
Biofrontera
United Therapeutics

back to top